In the case of GCV-treated U87-G-P/CD133-R-R-tTK or U87-G-P/OCT4/SOX2-R-R-tTK tumors, the CLARITY procedure allowed us to visualize small, approximately 500 μm in diameter, niches of therapy-surviving tumor cells. This evidence concerns the gene PROM1 and neoplasm.